[Ixoten therapy in malignant lymphomas].

Authors
Category Primary study
JournalActa medica Austriaca
Year 1979
Clinical experience with Ixoten (trofosfamide), a derivative of cyclophosphamide, is reported in 29 patients with malignant lymphomas. Daily doses of 150-300 mg p.o. and 6.000-200.000 mg total dose respectively, resulted in an 80% complete or partial remission. In addition to a dose dependent haematotoxicity, other side effects (gastrointestinal and/or hair loss) were almost negligible.
Epistemonikos ID: bc0270a5f12ef62598f942e22b7a6723e453a648
First added on: Jul 05, 2022